Nutrition interventions to treat low muscle mass in cancer.

Prado CM, Purcell SA, Laviano A. · 2020

Read Nutrition interventions to treat low muscle mass in cancer. by Prado CM, Purcell SA, Laviano A. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7113510.txt.

Introduction

Prado, Purcell, and Laviano review nutrition strategies for treating low muscle mass in cancer, in the Journal of Cachexia, Sarcopenia and Muscle. Many cancer patients lose muscle severely, at any stage of illness, and low muscle worsens outcomes. It often hides alongside obesity, so weight alone misses it.

Evidence for nutrition treatment is patchy, partly because few studies measure body composition well. The authors give working targets: 25 to 30 kilocalories and 1.0 to 1.5 grams of protein per kilogram of body weight daily. Supplements such as leucine, creatine, and fish oil are weighed, as are combined plans pairing nutrition with exercise and drugs. Longer, better-designed trials are the main need.

Catalog record

CREATORPrado CM, Purcell SA, Laviano A.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE84 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7113510

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Nutrition interventions to treat low muscle mass in cancer By Carla M. Prado, Sarah A. Purcell, Alessandro Laviano Published in: Journal of Cachexia, Sarcopenia and Muscle DOI: 10.1002/jcsm.12525 ABSTRACT Abstract Many patients with cancer experience poor nutritional status, which detrimentally impacts clinical outcomes. Poor nutritional status in cancer is primarily manifested by severe muscle mass (MM) depletion, which may occur at any stage (from curative to palliative) and often co‐exists with obesity. The objective of this article was to discuss gaps and opportunities related to the role of nutrition in preventing and reversing low MM in cancer. It also provides a narrative review of relevant nutritional interventions for patients capable of oral intake. The impact of nutrition interventions to prevent/treat low MM in cancer is not well understood, potentially due to the limited number of studies and of clinically viable, accurate body composition assessment tools. Additionally, the type of study designs, inclusion criteria, length of intervention, and choice of nutritional strategies have not been optimal, likely underestimating the anabolic potential of nutrition interventions. Nutrition studies are also often of short duration, and interventions that adapt to the metabolic and behavioural changes during the clinical journey are needed. We discuss energy requirements (25–30 kcal/kg/day) and interventions of protein (1.0–1.5 g/kg/day), branched‐chain amino acids (leucine: 2–4 g/day), β‐hydroxy β‐methylbutyrate (3 g/day), glutamine (0.3 g/kg/day), carnitine (4–6 g/day), creatine (5 g/day), fish oil/eicosapentanoic acid (2.0–2.2 g/day EPA and 1.5 g/day DHA), vitamin/minerals (e.g. vitamin D: 600–800 international units per day), and multimodal approaches (nutrition, exercise, and pharmaceutical) to countermeasure low MM in cancer. Although the evidence is variable by modality type, interventions were generally not specifically studied in the context of cancer. Understanding patients' nutritional requirements could lead to targeted prescriptions to prevent or attenuate low MM in cancer, with the overall aim of minimizing muscle loss during anti‐cancer therapy and maximizing muscle anabolism during recovery. It is anticipated that this will, in turn, improve overall health and prognostication including tolerance to treatment and survival. However, oncology‐specific interventions with more robust study designs are needed to facilitate these goals. INTRODUCTION Cancer is a disease affecting millions of people and one of the leading causes of death worldwide. Proper nutrition can alleviate symptom burden, improve health across the cancer continuum, and support cancer survivorship1 and is a hallmark of successful cancer treatment.2 The primary nutritional problem experienced by people with cancer—and likely the most impactful on prognosis—is muscle wasting (also termed sarcopenia or myopenia). Low muscle mass (MM) is common regardless of cancer stage (from curative to palliative) and is an independent predictor of poor physical function, lower quality of life, surgical complications, cancer progression, and reduced survival3, 4, 5, 6, 7. The overall prevalence of low MM is >50% in people with newly diagnosed cancer, which is considerably higher than the approximately 15% prevalence in healthy individuals of similar age (median 65 years old).8 This suggests that low MM contributes to the cancer process, either directly or indirectly. Further, as only about 10% of patients are underweight, this widespread phenomenon of low MM occurs independently of body weight or fat mass.9 Reversing low MM has the potential to improve cancer therapy outcomes, morbidities, and, ultimately, mortality. Given the role of MM and adipose tissue in oncological outcomes, strategies to optimize body composition are an important part of successful cancer therapy. Nutrition is one such modality that can favourably influence MM and adipose tissue. Herein, we provide a narrative review of the current state of the literature in this area, present an overview of nutrition strategies aimed at enhancing MM, and discuss strategies to mitigate limitations of nutrition interventions. BACKGROUND Low MM in cancer has been primarily studied under the auspices of refractory cancer cachexia, which is irreversible and non‐responsive to nutrition intervention.10 Therefore, skepticism exists in regard to the impact of nutrition interventions to countermeasure MM loss. While both conditions are associated with muscle depletion, low MM in cancer occurs independent of weight loss and therefore of cachexia. Notably, cachexia is also not frequent in all cancer types, while MM loss may occur more frequently, across cancer types, and in the presence of weight maintenance or weight gain.11, 12 Importantly, patients without refractory cachexia have anabolic potential and can present with gains in MM.13 Low MM in cancer also occurs at any disease stage.14, 15 Many believe that nutrition is not a priority once cancer is diagnosed or even that it can increase tumour growth,16 which is not founded on scientific evidence.17, 18, 19 The limited awareness of the impact of nutrition interventions on cancer outcomes can also be related to the (non‐exclusive) following issues: Limited use of accurate body composition tools: Although body weight and weight loss can be useful prognostic tools, anthropometric variables do not provide information on body composition alterations; in fact, BMI and BMI loss do not consistently relate to immediate clinical outcomes such as treatment toxicities.20 Utilization of sophisticated measurements of body composition in oncology is recent, with the first published study assessing MM using computerized tomography in cancer published in 2007.7 The use of accurate and reliable tools such as computerized tomography can not only quantify the impact of an intervention on the amount of MM but can also detect muscle attenuation, which is expressed in Hounsfield units and reflective of intramuscular adiposity (‘quality’ of the muscle). Furthermore, patients with cancer may also have increased skeletal muscle collagen content, which is associated with poor survival21; such parameters would not be detected by simple anthropometric assessments. Due to the historically limited availability of body composition measurements, the impact of nutrition interventions to reverse MM loss has been primarily focused on gains in total body weight, without a clear understanding of specific changes in muscle versus adipose tissue compartments.Different criteria for low MM: The level of MM below which people are diagnosed with ‘low MM’ remains a contentious topic.22 As discussed elsewhere,23 cut‐points depend on the methodological assessment, as well as the population and/or outcome of interest. Newer studies have also proposed sex‐specific percentiles and means and standard deviations for skeletal MM based on healthy adult populations.24, 25 Funding for nutrition research and small number of randomized controlled trials: Nutrition research receives a small proportion of funding,26 especially in comparison with pharmaceutical trials. This has reflected poorly on the funds available to conduct well‐designed (and costly) randomized controlled trials,27 which impact guideline recommendations and likely the trust of health care professionals across different disciplines.In the absence of anabolic medication, it could take months to completely restore muscle lost over a short period of time.Length of intervention insufficient to impact/measure muscle change: Short‐term interventions may not detect an anabolic response as demonstrated by improvements in MM. In oncology, MM loss may occur rapidly in some individuals and is especially pronounced in metastatic disease, wherein a 6.1% [95% confidence interval (CI) −8.4, −3.8, P < 0.001] MM decrease over 3 months has been reported, corresponding to 1.7 kg loss in male patients and 1.1 kg loss in female patients with advanced colorectal cancer.28 Even in patients with earlier stage cancer, MM loss ≥5.7% over median 14.3 months has been reported in approximately 20% of individuals (n = 1924).12 Conversely, regaining MM

Read the complete text